Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Ernest JP, Goh JJN, Strydom N, Wang Q, et al. Eur Respir J 2023;62:2300165.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ernest JP, Goh JJN, Strydom N, Wang Q, et al. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J 2023;62:2300165.
PMID: 37321622